Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03076333 · ClinicalTrials.gov registry record · NA

PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas

A NA study of Sarcoma, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
3
Enrollment target
1
Study location

NCT03076333: Completed NA study of Sarcoma, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT03076333 is a NA study of Sarcoma that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 3 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03076333, a NA study of Sarcoma, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

Purpose: To assess the utility of PET/MR in assessing response to neoadjuvant radiation therapy in the treatment of high grade sarcomas. Participants: Adult patients with potentially curable high grade sarcomas that are being treated at UNC with neoadjuvant radiation therapy followed by potentially curative surgical resection. Procedures (methods): Patients who are being treated for potentially curable high grade sarcomas with neoadjuvant radiation therapy followed by surgical resection undergo pre-treatment, mid-treatment, and post-treatment PET/MR and the response to treatment is assessed by evaluating change in size and FDG avidity. Patients then undergo curative intent resection and are followed. Their pathology is reviewed for treatment affect as is assessed by percent necrosis, size, and resection margins. Patients are followed and assessed for recurrence.

Primary Outcome

Primary endpoint is the determination of differences among response groups in PET activity estimates from PET/MR imaging at the midpoint of treatment as compared to baseline. The measure is computed as the change in mean SUV from the baseline PET-MR scan to the scan at the end of the second week of therapy. Treatment response will be determined on final pathological evaluation of the resected specimens in patients who undergo curative intent surgery after neoadjuvant radiation in high grade sarc

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST PET/MR

Study Locations (1)

North Carolina

  • UNC-Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2018-04-01
Est. Completion 2020-01-31
Phase NA

What the finished NCT03076333 record still lists

NCT03076333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which PET/MR is the first listed.

NCT03076333 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT03076333 about?

NCT03076333 is a clinical study titled "PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas". Purpose: To assess the utility of PET/MR in assessing response to neoadjuvant radiation therapy in the treatment of high grade sarcomas. Participants: Adult patients with potentially curable high grade sarcomas that are being treated at UNC with neoadjuvant radiation therapy followed by potentially...

What is the current status of trial NCT03076333?

This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2018-04-01. Estimated completion is 2020-01-31.

What conditions does trial NCT03076333 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT03076333?

The interventions under investigation include: PET/MR (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03076333?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03076333 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03076333's enrollment target sits among peer trials

3 123rd of 122 the lowest of 122 other Sarcoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03076333, the US trial registry maintained by the National Library of Medicine. NCT03076333 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.